Sun Pharma Canada launches PRWINLEVI, a novel topical treatment for Acne
Hyderabad/Mumbai, Sept. 27 -- : Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited , on Wednesday announced that PRWINLEVI (clascoterone cream 1% w/w) is now available in Canada.
WINLEVI is the first and only androgen receptor inhibitor indicated for the topical treatment of acne vulgaris (acne) in patients 12 years of age and older, the pharma company said in a release.
WINLEVI works differently from any other topical acne treatment.
Instead of a topical approach to acne treatment that focuses on follicular hyperkeratinisation, reducing inflammation or exerting antibacterial effects, WINLEVI is thought to reduce the effects of acne hormones on skin by disrupting the androgen cascade.
While the exact ...
To read the full article or to get the complete feed from this publication, please Contact Us